Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Pol

Showing results (191-200 of 441) with videos related to

Pageof 45
Sort By:
Antiviral Therapy|February 2, 2012
The role of adherence in virological suppression in patients receiving anti-HBV analoguesPhilippe Sogni, Maria Patrizia Carrieri, Hélène Fontaine, et al.
Kidney International|March 25, 2019
Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipientsRoberta D'Ambrosio, Maria Vinci, Marianna Franchina, et al.
World Journal of Gastroenterology|October 24, 2007
Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirinRoland El Braks, Nathalie Ganne-Carrie, Helene Fontaine, et al.
Canadian Association of Radiologists Journal = Journal L'Association Canadienne Des Radiologistes|August 11, 2023
Comparison Between Radial and Femoral Artery Access for Transarterial Chemoembolisation in Patients With Hepatocellular CarcinomaMohamed Hedjoudje, Maxime Barat, Anthony Dohan, et al.
Journal of Hepatology|March 15, 2012
Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infectionSimona Cosconea, Hélène Fontaine, Jean-François Méritet, et al.
The Journal of Experimental Medicine|September 26, 2007
Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patientsJérémie Decalf, Sandrine Fernandes, Randy Longman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 22, 2009
Does early antiretroviral treatment prevent liver fibrosis in HIV/HCV-coinfected patients?Firouzé Bani-Sadr, Pierre Bedossa, Eric Rosenthal, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 22, 2008
The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meetingStephen Barclay, Stanislas Pol, David Mutimer, et al.
Hepatology (Baltimore, Md.)|April 28, 2007
Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitopeSilvina Laura Malmassari, Qiang Deng, Hélène Fontaine, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 16, 2012
Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the LiverVincent Leroy, Lawrence Serfaty, Marc Bourlière, et al.
Pageof 45

Showing results (191-200 of 441) with videos related to

Sort By:
Pageof 45
Antiviral Therapy|February 2, 2012
The role of adherence in virological suppression in patients receiving anti-HBV analoguesPhilippe Sogni, Maria Patrizia Carrieri, Hélène Fontaine, et al.
Kidney International|March 25, 2019
Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipientsRoberta D'Ambrosio, Maria Vinci, Marianna Franchina, et al.
World Journal of Gastroenterology|October 24, 2007
Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirinRoland El Braks, Nathalie Ganne-Carrie, Helene Fontaine, et al.
Canadian Association of Radiologists Journal = Journal L'Association Canadienne Des Radiologistes|August 11, 2023
Comparison Between Radial and Femoral Artery Access for Transarterial Chemoembolisation in Patients With Hepatocellular CarcinomaMohamed Hedjoudje, Maxime Barat, Anthony Dohan, et al.
Journal of Hepatology|March 15, 2012
Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infectionSimona Cosconea, Hélène Fontaine, Jean-François Méritet, et al.
The Journal of Experimental Medicine|September 26, 2007
Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patientsJérémie Decalf, Sandrine Fernandes, Randy Longman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 22, 2009
Does early antiretroviral treatment prevent liver fibrosis in HIV/HCV-coinfected patients?Firouzé Bani-Sadr, Pierre Bedossa, Eric Rosenthal, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 22, 2008
The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meetingStephen Barclay, Stanislas Pol, David Mutimer, et al.
Hepatology (Baltimore, Md.)|April 28, 2007
Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitopeSilvina Laura Malmassari, Qiang Deng, Hélène Fontaine, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 16, 2012
Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the LiverVincent Leroy, Lawrence Serfaty, Marc Bourlière, et al.
Pageof 45